Adrenomed AG

Car­dio­vas­cu­lar and Sep­sis, Adre­cizumab Ph 2, bio­mark­er-guid­ed, mon­o­clo­n­al anti­body for sep­tic shock; to­p­li­nee da­ta re­leased late Feb. Adre­cizumab showed low­er all-cause mor­tal­i­ty for treat­ed pts com­pared to place­bo (28% mor­tal­i­ty rate in 28-day fol­low-up). De­tailed da­ta com­ing in fol­low­ing few months. [more in­for­ma­tion]

AM-Pharma B.V.

Treat­ing sep­sis as­so­ci­at­ed acute kid­ney in­jury (AKI) with pro­pri­e­tary re­com­bi­nant al­ka­line phos­pha­tase (re­cAP). Re­sults from Ph 2 trial in 300+ pts, de­mon­s­trat­ed rel­a­tive im­prove­ment of 40%+ OS in re­cAP group. Ini­ti­at­ing Ph 3 in Q3 2020 – in­ter­im look (n=400) exp Q3 2021 (P end­point: Day 28 all-cause mor­tal­i­ty). [more in­for­ma­tion]

Anokion

Anokion is har­ness­ing the pow­er of na­t­u­ral im­mune equilib­ri­um to de­vel­op so­lu­tions for anti­gen-spe­cif­ic im­mune tol­er­ance. [more in­for­ma­tion]

Antengene

Op­er­a­tor of a clin­i­cal-stage bio-phar­ma­ceu­ti­cal plat­form in­tend­ed to fo­cus on drug dis­cov­ery, clin­i­cal de­vel­op­ment and the com­mer­cial­iza­tion of in­no­va­tive ther­a­peu­tics. the com­pany's plat­form aims to pro­vide first-in-class an­ti-can­cer drug treat­ments for re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma, lym­pho­mas and solid tu­mors, en­abling physi­cians to meet un­met med­i­cal needs in Asia. [more in­for­ma­tion]

Apexigen

CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]

Apic Bio

De­vel­op­er of a gene ther­a­py pro­pri­e­tary plat­form in­tend­ed to treat rare dis­eas­es with com­plex mech­anisms. The com­pany's plat­form of­fers APB-101 which tar­gets the liv­er by way of an AAV de­liv­ered Du­al Func­tion Vec­tor, en­abling doc­tors to treat rare, de­v­as­tat­ing neu­ro­log­i­cal and liv­er dis­eas­es. [more in­for­ma­tion]

Arkuda Therapeutics

Own­er and op­er­a­tor of a ther­a­peu­tics com­pany in­tend­ed to im­prove the lives of pa­tients with neu­ro­log­i­cal dis­eas­es. Main­ly fo­cus­ing on Fron­totem­po­ral De­men­tia. The com­pany is cur­rent­ly op­er­at­ing in Stealth mode. [more in­for­ma­tion]

AsclepiX Therapeutics

AX­T107 de­mon­s­trat­ed ef­fi­ca­cy and dura­bil­i­ty in rab­bit and mouse mod­els that is su­pe­ri­or to stan­dard of care Eylea. [more in­for­ma­tion]

ATAI Life Sciences AG

ATAI is a glob­al biotech com­pany builder that lev­er­ages a de­cen­tral­ized, tech­nol­o­gy- and da­ta-driv­en plat­form mod­el to serve mil­lions of peo­ple suf­fer­ing from men­tal health di­s­or­ders. ATAI is com­mitt­ed to ac­quir­ing and ef­fi­cient­ly de­vel­op­ing in­no­va­tive treat­ments that ad­dress sig­ni­f­i­cant un­met med­i­cal needs and lead to paradigm shifts in the men­tal health space. [more in­for­ma­tion]

Axial Biotherapeutics, Inc.

The com­pany's bio­ther­a­peu­tics prod­ucts har­ness the gut-brain axis to de­vel­op nov­el Cen­tral Ner­vous Sys­tem (CNS) Ther­a­peu­tics to im­prove the qual­i­ty of life for peo­ple with CNS dis­eas­es and di­s­or­ders, pro­vid­ing med­i­cal pro­fes­sio­n­als and health­care in­sti­tu­tions with a new ap­proach for di­ag­nos­ing and treat­ing PD and ASD and po­ten­tial­ly other CNS dis­eas­es. [more in­for­ma­tion]

Azitra

The com­pany lev­er­ages mi­cro­bi­o­log­i­cal bac­te­ria strains tech­nol­o­gy to fa­cil­i­tate the treat­ment of ecze­ma, ichthyo­sis vul­garis, in­flam­ma­to­ry skin, ir­ri­tat­ed skin and or­phan skin dis­eas­es in­clud­ing Nether­ton syn­drome, en­abling der­ma­tol­o­gists to treat pa­tients with chron­ic and acute skin di­s­or­ders [more in­for­ma­tion]

Boundless Bio

De­vel­op­er of nov­el can­cer ther­a­peu­tics in­tend­ed to un­der­s­tand and treat in­trace­able can­cers. The com­pany is in the pro­cess of de­vel­op­ing a nov­el class of can­cer drugs and ex­trachro­mo­so­mal DNA (ecD­NA) that elim­i­nates can­cer cells abil­i­ty to em­ploy ecD­NA to sur­vive, en­abling health­care pro­fes­sio­n­als to treat most-dif­fi­cult can­cers. [more in­for­ma­tion]

Cadent Therapeutics

Ca­dent Ther­a­peu­tics is cre­at­ing break­through ther­a­pies for the treat­ment of move­ment di­s­or­ders and cog­ni­tive im­pair­ment. The com­pany has an ex­clu­sive li­cense and col­lab­o­ra­tion agree­ment with No­var­tis to de­vel­op a neg­a­tive al­los­ter­ic mo­d­u­la­tor, now in Phase 1 clin­i­cal studies for the treat­ment of treat­ment re­sis­tant de­pres­sion. [more in­for­ma­tion]

Candesant Biomedical

Can­de­sant Biomed­i­cal is de­vel­op­ing a com­pelling prod­uct to un­lock the po­ten­tial of the sweat con­trol mar­ket. Fur­ther, the prod­uct will pro­vide a great val­ue to the con­sumer with an eco­nom­ic in­cen­tive to the treat­ing physi­cians. [more in­for­ma­tion]

Cellestia Biotech AG

Our drug dis­cov­ery plat­form is built on a unique mode of ac­tion of tar­get­ing pro­tein-pro­tein in­ter­ac­tions (PPI) with small molecules. Celles­tia is com­plet­ing a Phase l first-in-man clin­i­cal trial with CB-103 treat­ing can­cer pa­tients in the EU. Dai­ly treat­ment with CB-103 has been so far very well tol­er­at­ed, con­firm­ing the ex­cel­lent safe­ty and fa­vor­able phar­ma­coki­net­ic pro­file. [more in­for­ma­tion]

CerSci Therapeutics

De­vel­op­ing a new gen­er­a­tion of non-opi­oid medicines to treat acute post-op­er­a­tive and chron­ic neu­ro­path­ic pain. Lead pro­gram in Phase 1 (MAD/SAD/Food Ef­fect), CT-044, tar­get­ing re­ac­tive spe­cies that cause neu­ro­n­al ion chan­nel hy­per-sen­si­ti­za­tion, known to trig­ger pain. [more in­for­ma­tion]

Clerio Vision, Inc.

De­vel­op­er of vi­sion cor­rec­tion tech­nolo­gies in­tend­ed to help in the treat­ment of re­frac­tive er­ror. The com­pany's of­fer­ings in­clude a fem­tose­cond las­er tech­nol­o­gy that has the po­ten­tial to rev­o­lu­tion­ize the vi­sion cor­rec­tion mar­ket, en­abling physi­cians to cure the re­frac­tive in­dex in the hu­man cornea. [more in­for­ma­tion]

Cognition Therapeutics

Cog­ni­tion’s lead can­di­date, CT1812 (Elay­ta™), is a nov­el first-in-class, oral­ly avai­l­able small molecule that has shown the po­ten­tial in ini­tial clin­i­cal studies to nor­mal­ize pro­tein traf­fick­ing and lipid metabolism path­ways that are dis­rupt­ed in Alzheimer’s dis­ease and to al­low the pro­tec­tion and res­to­ra­tion of sy­naps­es. [more in­for­ma­tion]

Complexa

De­vel­op­er of ther­a­pies for the treat­ment of in­flam­ma­to­ry and metabolic dis­eas­es. The com­pany's clin­i­cal stage plat­form fo­cus­es on the re­ser­ach and de­vel­op­ment of se­lec­tive and re­v­ersi­ble en­doge­nous hu­man cell sig­nal­ing tech­nolo­gies tar­get­ing or­phan dis­eas­es. [more in­for­ma­tion]

Diasome

De­vel­op­er of nov­el and cell tar­get­ed ther­a­pies de­signed to treat di­a­betes, obe­si­ty and other metabolic con­di­tions. The com­pany's ther­a­pies in­clude ISLE-1 (In­Sulin Liv­er Ef­fect) Phase 2b study of HDV-In­sulin in sub­jects with Type 1 di­a­betes, en­abling pa­tients to get nov­el pro­pri­e­tary liv­er tar­get­ed in­sulins for both Type 1 and Type 2 di­a­betes eas­i­ly. [more in­for­ma­tion]

Enterin

De­vel­op­er of nov­el drugs in­tend­ed to re­pair the dys­func­tio­n­al gut-brain axis. The com­pany's drugs dis­places &al­pha;-synu­clein ag­gre­gates and re­s­tores nor­mal sig­nal­ing be­tween the gut and the brain, en­abling pa­tients with Parkin­son's dis­ease and other neu­rode­gen­er­a­tive con­di­tions to have a bet­ter the qual­i­ty of life. [more in­for­ma­tion]

EOC Pharma

EOC is a Shang­hai-based bio­phar­ma­ceu­ti­cal com­pany that is fo­cused on the in-li­cens­ing of in­no­va­tive glob­al on­col­o­gy prod­ucts, and de­vel­op­ing, man­u­fac­tur­ing and com­mer­cial­iz­ing them for the Chi­na mar­ket. [more in­for­ma­tion]

Foghorn Therapeutics Inc.

Through its Gene Traff­ic Con­trol™ Prod­uct Plat­form, Foghorn® Ther­a­peu­tics is dis­cov­er­ing and de­vel­op­ing an un­prece­dent­ed class of medicines tar­get­ing dis­eas­es with ge­net­i­cal­ly de­ter­mined de­pen­den­cies in the chro­matin reg­u­la­to­ry sys­tem. [more in­for­ma­tion]

Forbius

Se­lec­tive in­hibi­tors of TGF Be­ta & EGFR path­ways. AACR: (+) Ph 1 da­ta. 3 on­go­ing Ph 2 trials (SCCHN, NS­CLC, TN­BC); ad­dl Ph 1 trials in IO, Sys­temic Scle­ro­sis & Myelo­fi­bro­sis [more in­for­ma­tion]

HemoShear Therapeutics

He­moS­hear Ther­a­peu­tics dis­cov­ers nov­el bi­o­log­i­cal tar­gets and ad­vances drug pro­grams to treat metabolic di­s­or­ders with sig­ni­f­i­cant un­met pa­tient need. The Com­pany's lead pro­grams in pro­pi­on­ic and methyl­malon­ic acidemia (rare in­born er­rors of metabolism) will en­ter phase 2 studies this year. [more in­for­ma­tion]

Horama

The com­pany's lead can­di­date is HO­RA-PDE6B, which is in Phase I/II clin­i­cal trials with an in­di­ca­tion in PDE6B re­tini­tis pig­men­tosa. The se­cond prod­uct will en­ter in the clin­ic in H1 2019 The com­pany raised EUR 22.5 mil­lion of Se­ries B ven­ture fund­ing from Kur­ma Part­n­ers, Pon­ti­fax Ven­ture Cap­i­tal, Fund+ on Novem­ber 8, 2017. [more in­for­ma­tion]

Incysus Therapeutics

The com­pany's ser­vices fo­cus on uti­l­iz­ing ge­net­i­cal­ly mod­i­fied gam­ma-del­ta T cells across a Drug Re­sis­tance Im­munother­a­py (DRI) plat­form that ad­dress­es the chal­lenges faced while tar­get­ing cold, low mu­ta­tion can­cers, en­abling the tar­get­ing of ma­lig­nant cells and po­ten­tial­ly more ef­fec­tive treat­ments for pa­tients with dif­fi­cult-to-treat solid tu­mor can­cers. [more in­for­ma­tion]

ISA Pharmaceuticals BV

is an im­munother­a­py com­pany de­vel­op­ing ra­tio­n­al­ly de­signed, ful­ly syn­thet­ic im­munother­a­peu­tics against can­cer and per­sis­tent vi­ral in­fec­tions. The Com­pany has built a pro­pri­e­tary im­munother­a­py plat­form based on the Syn­thet­ic Long Pep­tide (SLP®) con­cept and AM­PLI­VANT®tech­nol­o­gy. [more in­for­ma­tion]

jCyte

De­vel­op­er of cell-based tech­nol­o­gy in­tend­ed to cure re­tini­tis pig­men­tosa. The com­pany's ther­a­py used reti­nal pro­gen­i­tor cells can se­crete growth fac­tors to res­cue da­m­aged reti­nal cells which helps in treat­ing a de­gen­er­a­tive eye dis­ease that ul­ti­mate­ly caus­es blind­ness en­abling, pa­tients af­flict­ed by con­di­tions that lead to blind­ness, pre­serve and re­s­tore sight. [more in­for­ma­tion]

KAHR medical

KAHR Med­i­cal de­vel­ops nov­el fu­sion pro­tein phar­ma­ceu­ti­cals for the treat­ment of can­cer and au­toim­mune dis­eas­es. [more in­for­ma­tion]

Kineta Inc.

Kine­ta (Pri­vate) - whol­ly owned pre­clin­i­cal an­ti-VIS­TA (in­nate im­mune tar­get) anti­body re­pro­grams the tu­mor mi­croen­vi­ron­ment and is dif­fer­en­ti­at­ed from other im­munother­a­pies by block­ing sup­pres­sive cells in cold tu­mors. $520M deal with Pfiz­er for its small molecule RIG-I im­munother­a­py and $360M+ deal with Ge­nen­tech for KCP506, pre­clin­i­cal, non-opi­oid for chron­ic pain. [more in­for­ma­tion]

Maverick Therapeutics

Mav­er­ick Ther­a­peu­tics is a biotech com­pany fo­cused on im­prov­ing the lives of pa­tients with solid tu­mor can­cers by de­vel­op­ing break­through T cell im­munother­a­pies with im­proved safe­ty and ef­fi­ca­cy. [more in­for­ma­tion]

Minoryx Therapeutics

Oral PPAR&gam­ma; ag­on­ist, MIN-102, in Piv­o­tal Ph 2/3 for X-linked ALD and Ph 2 Frie­drich’s Ataxia; da­ta for both ex­pect­ed by end of 2020. VC in­ves­tors in­clude Kur­ma, Ysios, Fund+, Roche, Id­in­vest, etc [more in­for­ma­tion]

Neurana Pharmaceuticals

The pri­mary ob­jec­tive of the study was to as­sess the ef­fi­ca­cy of vari­ous dai­ly dos­es of tolperi­sone to de­ter­mine the dose to be used for the planned Phase 3 clin­i­cal pro­gram. Giv­en the pos­i­tive re­sults of the STAR Study, Neu­ra­na plans to conduct an end-of-Phase 2 meet­ing with the FDA in the first quar­ter of 2020 and ini­ti­ate Phase 3 clin­i­cal studies of tolperi­sone lat­er in 2020. [more in­for­ma­tion]

NorthSea Therapeutics

First-in class, oral, struc­tu­ral­ly en­gi­neered fat­ty acids [SE­FAs] ad­dress­ing NASH and as­so­ci­at­ed metabolic di­s­or­ders via unique tar­get­ing of path­ways reg­u­lat­ing metabolism, oxida­tive stress, in­flam­ma­tion, and fi­bro­sis. $40m Se­ries B (Jan 2020) with ven­Bio Part­n­ers (lead) and Sofin­no­va In­vest­ments. [more in­for­ma­tion]

Prometheus Biosciences, Inc.

Prometheus Bio­s­ciences was found­ed in 2016 by Scott Glenn and Stephan Tar­gan, MD, who pre­vi­ous­ly co-found­ed San­tarus and Prometheus Lab­o­ra­to­ries. Prometheus Bio­s­ciences will serve as the name for the com­bined com­pa­nies Pre­ci­sion IBD and Prometheus Lab­o­ra­to­ries, Inc. cre­at­ed through the June 2019 ac­qui­si­tion of Prometheus Lab­o­ra­to­ries by Pre­ci­sion IBD. [more in­for­ma­tion]

Sensei Biotherapeutics

The com­pany is us­ing its pro­pri­e­tary drug dis­cov­ery plat­form, called SPIR­IT, to dis­cov­er and de­vel­op both vaccines and T-cell ther­a­pies, in­clud­ing SN­S301, its clin­i­cal stage can­cer vaccine, and SNS-723, its cell ther­a­py pro­gram in pre­clin­i­cal de­vel­op­ment for solid tu­mors and he­ma­to­log­i­cal can­cers. [more in­for­ma­tion]

Solebury Trout

With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]

SphingoTec GmbH

The tests are be­ing im­ple­ment­ed on the Com­pany’s own point-of-care im­munoas­say an­a­lyz­er plat­form ac­quired form Sam­sung in 2018 that is ful­ly de­vel­oped and was orig­i­nal­ly launched in 2012 and was sold more than 1,800 times since then. [more in­for­ma­tion]

Spruce Biosciences

The com­pany’s lead prod­uct can­di­date, til­dac­er­font, is an in­vesti­ga­tio­n­al oral drug that is be­ing eval­u­at­ed in studies for the treat­ment of con­geni­tal adre­nal hy­per­pla­sia (CAH). The com­pany al­so plans to eval­u­ate til­dac­er­font in other dis­eas­es im­pact­ed by el­e­vat­ed ACTH or adre­nal an­dro­gens. [more in­for­ma­tion]

sterna biologicals

By tar­get­ing tran­scrip­tion fac­tors that play a cen­tral role in reg­u­lat­ing Th1- and Th2-driv­en in­flam­ma­to­ry mech­anisms, the Com­pany’s pro­pri­e­tary DNAzyme-based drug can­di­dates can in­ter­vene with up­stream in­flam­ma­to­ry pro­cess­es to ad­dress re­lat­ed dis­eas­es more ef­fec­tive­ly. Ster­na cur­rent­ly has four pro­grams in phase 2 de­vel­op­ment. [more in­for­ma­tion]

Sublimity Therapeutics

Eval­u­at­ing re­for­mu­lat­ed Cy­clos­porine as top­i­cal treat­ment in pa­tients with mod­er­ate to se­vere UC. Lead pro­gram in Phase 2b trial for mod­er­ate to se­vere Ul­cer­a­tive Coli­tis. Can­di­date is an oral calcineurin in­hibi­tor that de­liv­ers ther­a­peu­tic lev­els of the drug di­rect­ly to the in­flamed colon, while min­i­miz­ing side ef­fects typ­i­cal­ly as­so­ci­at­ed with sys­temic im­muno­mo­d­u­la­tors. [more in­for­ma­tion]

Teon Therapeutics

Pipe­line of next-gen­er­a­tion can­cer ther­a­peu­tics tar­get­ing GPCRs in­clud­ing a high­ly-spe­cif­ic A2B an­ta­g­on­ist and EP4 an­ta­g­on­ist, both slat­ed to en­ter Phase 1b trials in 2021. [more in­for­ma­tion]

Vaccitech Limited

Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces and main­tains CD8+ T-cells at the max­i­mum lev­els pub­lished to date. Ph1/2 for HPV and HBV im­munother­a­pies ini­ti­at­ing 1H20. Two can­cer im­munother­a­py pro­grams (per­so­n­al­ized vaccine and MAGE-NYE­SO ther­a­peu­tics) en­ter clin­ic in 2020. Two ChA­dOx1 vaccines for coro­n­avirus­es with Ox­ford Univ fund­ed by CEPI – COVID-19 (an­nounced 3/10/20) and MERS (Ph.1 com­plete). $150M fund­ing at Jen­n­er In­sti­tute and com­pany raised $48M since for­ma­tion in 2016 [more in­for­ma­tion]

ViaCyte, Inc.

The PEC-Di­rect™ prod­uct can­di­date de­liv­ers the pan­cre­at­ic pro­gen­i­tor cells in a non-im­muno­pro­tec­tive de­vice and is be­ing de­vel­oped for type 1 di­a­betes pa­tients who have hy­po­g­lycemia un­aware­ness, ex­treme glycemic la­bil­i­ty, and/or re­cur­rent se­vere hy­po­g­lycemic epi­sodes. [more in­for­ma­tion]

Viramal Limited

Vi­ra­mal is an emerg­ing spe­cial­ty phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of glob­al ther­a­peu­tics that im­prove the qual­i­ty of wo­m­en’s health world­wide. The com­pany is de­vel­op­ing in­no­va­tive prod­ucts that tar­get un­met ther­a­peu­tic ar­eas through the use of its unique phar­ma­ceu­ti­cal de­liv­ery plat­forms and tech­nolo­gies. [more in­for­ma­tion]

Xoc Pharmaceuticals

Xoc Phar­ma­ceu­ti­cals has a chem­istry based small molecule tech­nol­o­gy plat­form that has de­vel­oped a pipe­line of molecules in­clud­ing two that are in Phase I studies tar­get­ing Neu­rol­o­gy in­di­ca­tions (Parkin­son’s dis­ease and Mi­graine pre­ven­tion). Xoc raised $30M in a Se­ries A from NEA and is led by a team from MAP Phar­ma­ceu­ti­cals. [more in­for­ma­tion]

Xylonix

Dubbed as on­co-partha­na­tos agents, Xy­lonix’ lead de­vel­op­ment can­di­dates, C005D and C008D, are be­ing de­vel­oped for fu­ture in­di­cat­ed use as monother­a­py or in com­bi­na­tion with other lead­ing im­munother­a­pies such as im­mune check­point in­hibi­tors or CS­F1R in­hibi­tors. [more in­for­ma­tion]

Zikani Therapeutics

Zikani Ther­a­peu­tics is us­ing its in­no­va­tive chem­istry tech­nol­o­gy plat­form to de­vel­op nov­el Ri­bo­some Mo­d­u­lat­ing Agents (RMAs). We are fo­cused on de­vel­op­ing and com­mer­cial­iz­ing ther­a­peu­tics for pa­tients with limit­ed treat­ment op­tions. Zikani’s TUR­BO-ZM plat­form al­lows rapid syn­th­e­sis of nov­el com­pounds that can be op­ti­mized to mo­d­u­late the ri­bo­some in a dis­ease spe­cif­ic man­n­er. [more in­for­ma­tion]